Patents by Inventor Diego Fernando Domenico BROGGINI

Diego Fernando Domenico BROGGINI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE
    Publication number: 20240000778
    Abstract: The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g.
    Type: Application
    Filed: May 15, 2023
    Publication date: January 4, 2024
    Applicant: ASTEX THERAPEUTICS LTD
    Inventor: Diego Fernando Domenico BROGGINI
  • PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE
    Publication number: 20230416252
    Abstract: The present application generally relates to several processes for the preparation of (6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one: Compound (I).
    Type: Application
    Filed: October 11, 2021
    Publication date: December 28, 2023
    Inventors: Subha MUKHERJEE, William P. GALLAGHER, Christopher Robert JAMISON, Carolyn S. WEI, Sergei KOLOTUCHIN, Amarjit SINGH, Nicolas CUNIERE, Chris SFOUGGATAKIS, Adrian ORTIZ, Steven R. WISNIEWSKI, Bin ZHENG, Helen Y. LUO, Sébastien François Emmanuel LEMAIRE, Cyril BEN HAÏM, Kostiantyn CHERNICHENKO, Diego Fernando Domenico BROGGINI, Simon Albert WAGSCHAL, Duy Chi Trung CAO, Karl REUTER, Björn SCHMALZBAUER, Philipp KOSCHKER, Martin D. EASTGATE, Dimitri SKLIAR, Alexander ZHDANKO, Christos XIOURAS, Matthew Penfield MOWER, Ngoc Duc TRAN, Ramdane RAHMANI, Xavier Jean-Marie JUSSEAU, Kiran MATCHA, Luca Alessandro PEREGO
  • BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer
    Publication number: 20230203011
    Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: December 19, 2022
    Publication date: June 29, 2023
    Inventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
  • Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
    Patent number: 11684620
    Abstract: The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g. cancer.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: June 27, 2023
    Assignee: ASTEX THERAPEUTICS LTD
    Inventor: Diego Fernando Domenico Broggini
  • Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
    Patent number: 11542247
    Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 3, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
  • NOVEL SYNTHETIC OPTIONS TOWARDS THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE
    Publication number: 20220144836
    Abstract: Highly efficient methods are provided for preparing key intermediates in the synthesis of Compound (I), which are broadly applicable and can provide selected components having a variety of substituents groups.
    Type: Application
    Filed: April 10, 2020
    Publication date: May 12, 2022
    Inventors: Nicolas CUNIERE, Yu FAN, Sergei KOLUTUCHIN, Subha MUKHERJEE, Eric M. SIMMONS, Amarjit SINGH, Carolyn S. WEI, Yi XIAO, Changxia YUAN, Bin ZHENG, Simon Albert WAGSCHAL, Diego Fernando Domenico BROGGINI, Duy Chi Trung CAO, Kostiantyn CHERNICHENKO, Sebastien Francois Emmanuel LEMAIRE, Cyril BEN HAÏM
  • Compounds
    Patent number: 11155555
    Abstract: The invention relates to new quinoxaline, quinoline and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: October 26, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Helene France Solange Colombel, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
  • PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE
    Publication number: 20210169877
    Abstract: The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g.
    Type: Application
    Filed: December 17, 2020
    Publication date: June 10, 2021
    Applicant: ASTEX THERAPEUTICS LTD
    Inventor: Diego Fernando Domenico BROGGINI
  • Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
    Patent number: 10898482
    Abstract: The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g. cancer.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: January 26, 2021
    Assignee: ASTEX THERAPEUTICS LTD
    Inventor: Diego Fernando Domenico Broggini
  • NEW COMPOUNDS
    Publication number: 20200255401
    Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: September 22, 2016
    Publication date: August 13, 2020
    Inventors: Patrick Rene ANGIBAUD, Diego Fernando Domenico BROGGINI, Filip Albert C CUYCKENS, Steven Anna HOSTYN, Russell Mark JONES, Olivier Alexis Georges QUEROLLE, Wim VERMEULEN
  • Quinoxaline derivatives useful as FGFR kinase modulators
    Patent number: 10421747
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: September 24, 2019
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Wim Vermeulen, Steven Anna Hostyn, Filip Albert Celine Cuyckens, Russell Mark Jones, Diego Fernando Domenico Broggini
  • Process for the preparation of histamine H3 receptor modulators
    Patent number: 10323002
    Abstract: The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: June 18, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Diego Fernando Domenico Broggini, Vit Lellek, Susanne Lochner, Neelakandha S. Mani, Adrian Maurer, Daniel J. Pippel, Lana K. Young
  • QUINOXALINE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS
    Publication number: 20180186775
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: December 28, 2017
    Publication date: July 5, 2018
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Wim VERMEULEN, Steven Anna HOSTYN, Filip Albert Celine CUYCKENS, Russell Mark JONES, Diego Fernando Domenico BROGGINI
  • Quinoxaline derivatives useful as FGFR kinase modulators
    Patent number: 9902714
    Abstract: The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: February 27, 2018
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Wim Vermeulen, Steven Anna Hostyn, Filip Albert Celine Cuyckens, Russell Mark Jones, Diego Fernando Domenico Broggini
  • PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE
    Publication number: 20180021332
    Abstract: The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g.
    Type: Application
    Filed: February 9, 2016
    Publication date: January 25, 2018
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventor: Diego Fernando Domenico BROGGINI
  • PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS
    Publication number: 20180022704
    Abstract: The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.
    Type: Application
    Filed: October 4, 2017
    Publication date: January 25, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Diego Fernando Domenico BROGGINI, Vit LELLEK, Susanne LOCHNER, Neelakandha S. MANI, Adrian MAURER, Daniel J. PIPPEL, Lana K. YOUNG
  • Process for the preparation of histamine H3 receptor modulators
    Patent number: 9809547
    Abstract: The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: November 7, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Diego Fernando Domenico Broggini, Vit Lellek, Susanne Lochner, Neelakandha S. Mani, Adrian Maurer, Daniel J. Pippel, Lana K. Young
  • QUINOXALINE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS
    Publication number: 20170101396
    Abstract: The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: March 26, 2015
    Publication date: April 13, 2017
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Wim VERMEULEN, Steven Anna HOSTYN, Filip Albert Celine CUYCKENS, Russell Mark JONES, Diego Fernando Domenico BROGGINI
  • PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS
    Publication number: 20170057919
    Abstract: The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 2, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Diego Fernando Domenico BROGGINI, Vit LELLEK, Susanne LOCHNER, Neelakandha S. MANI, Adrian MAURER, Daniel J. PIPPEL, Lana K. YOUNG